StocksMediumUpdated•Originally published 14 October 2026•Updated 14 October 2026•
1 min read
Vanda Pharmaceuticals Halts VQW-765 Development After Phase III Failure
Key Facts
1Vanda Pharmaceuticals' Phase III study of VQW-765 for social anxiety disorder did not meet its primary endpoint.
2The company stated that VQW-765 was safe and well tolerated, consistent with prior clinical studies.
Vanda Pharmaceuticals has decided to put the VQW-765 development program on hold following the study's failure to meet its primary goal. According to a company statement via PR Newswire, clinical data from the Phase III trial for social anxiety disorder failed to demonstrate a statistically significant improvement in the primary efficacy endpoint compared to the control group.
The company noted that while VQW-765 was safe and well tolerated, consistent with prior findings, the lack of efficacy led to the suspension of the program. VNDA closed at $4.3 on October 13, 2026, after reaching a session high of $4.54 and a low of $4.28.